The Expanding Role of Proteasome Inhibitors for the Treatment of Multiple Myeloma

The Expanding Role of Proteasome Inhibitors for the Treatment of Multiple Myeloma

On-Demand Webcast

Thomas G. Martin, MD
Clinical Professor of Medicine
UCSF Medical Center
San Francisco, California

Joseph R. Mikhael, MD, MEd, FRCPC
Professor, Applied Cancer Research and Drug Discovery Division
City of Hope Cancer Center
Translational Genomics Research Institute
Phoenix, Arizona

Agner Paner, MD
Assistant Professor
Rush University Medical Center
Chicago, Illinois

Keith Stewart, MB, ChB
Vice-President, Cancer
Director, Princess Margaret Cancer Program
University Health Network
Toronto, Canada

Peter Voorhees, MD
Levine Cancer Institute - Morehead
Atrium Health
Charlotte, North Carolina


Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email


This activity is designed for U.S. hematologists, medical oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc) who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.


Multiple myeloma (MM) is the second most common hematological malignancy in the US, with over 32,000 new diagnoses and nearly 13,000 deaths estimated to occur in 2019. MM is characterized by the clonal proliferation of malignant plasma cells and the over-production of monoclonal immunoglobulin (M-protein). The majority of patients with MM develop resistance and/or relapse after the first-line therapy, even patients eligible for high-dose therapy with autologous stem cell transplantation (ASCT). The disease trajectory of most patients involves cycling through response, remission, and relapse, with diminishing depth and duration of response over time and the eventual progression to treatment-refractory relapse and deathThis need led to the major strides that have been made in the management of MM with the emergence of a number of novel agents from several different classes that exhibit greater efficacy, more convenient administration routes, and safer profiles. New and emerging proteasome inhibitors (PIs) have presented very positive results in clinical trials. However, clinicians are now confronted with a large field of possible treatment combinations, and must consider varying mechanisms of action, toxicity profiles, and patient factors when selecting and sequencing treatments. Therefore, to reach providers positioned to effect meaningful change within the management of MM with PIs and positively impact patient care, education that centers on the latest evidence and strategies to overcome challenges within the treatment of MM is warranted and necessary. 

This webcast aims to close the knowledge gap so that healthcare providers are positioned to effect meaningful change within the management of MM and positively impact patient care.


After participating in this activity, learners should be better able to:

  • Describe the pharmacology, safety, and efficacy of new and emerging PI agents for MM treatment  
  • Evaluate clinical and real-world data regarding the effectiveness and toxicity profiles of therapeutic combinations 
  • Incorporate PIs to treatment strategies that are informed by phenotypic, genetic, and clinical factors to optimize sensitization to treatment and improve patient outcomes  

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: September 30, 2020
Expiration Date: September 30, 2021
Estimated Time to Complete: 125 minutes

There is no fee associated with this activity.


Supported by educational grants from: Amgen, Takeda Oncology



In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 2.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.00 contact hours. 


This internet enduring, knowledge-based activity (Universal Activity Number:JA0006201-0000-20-173-H01-P) has been approved for a maximum of 2.00 contact hours (.200 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is November 28, 2021. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 2.00 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Christopher Bolwell, Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers, Shannon Stevenson, and Griselda Zuccarino-Catania. 

Christopher Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their products or services.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

No other planner has disclosed a relevant financial relationship with any commercial interest.


The faculty has reported the following:

Thomas G. Martin: Consultant-GSK, Legend; Grant/Research Support-Amgen, Janssen, Sanofi, Seattle Genetics

Joseph Mikhael: Consultant-Amgen, Celgene, GSK, Janssen, Karyopharm, Sanofi, Takeda

Agne Paner: Consultant-AbbVie, Amgen, Celgene, Janssen, Karyopharm

Keith Stewart: Advisory Board-Veritas Genetics; Consultant-BMS, Ono Pharmaceuticals; Grant/Research Support-Amgen, BMS, Celgene, Janssen

Peter Voorhees: Consultant-Celgene, Janssen, Novartis Pharmaceuticals, Oncopeptides, Tenebio


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.